

Long-term respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination

Elena Mitsi^{1,2*}, Mariana O. Diniz^{3*}, Jesús Reiné^{1,2}, Andrea M. Collins², Ryan Robinson², Angela Hyder-Wright², Madlen Farrar², Konstantinos Liatsikos², Josh Hamilton², Onyia Onyema², Britta C. Urban^{1,2}, Carla Solorzano^{1,2}, Teresa Lambe^{1,5}, Simon J. Draper⁴, Daniela Weiskopf⁶, Alessandro Sette^{6,7}, Mala K. Maini^{3^} and Daniela M. Ferreira^{1,2^}

¹Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.

²Department of Clinical Science, Liverpool School of Tropical Medicine, Liverpool, UK.

³Division of Infection and Immunity and Institute of Immunity and Transplantation, UCL, London, UK.

⁴Department of Biochemistry, University of Oxford, Oxford, UK

⁵Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK

⁶Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, USA.

⁷Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, USA.

*Joint first authors

^Joint senior authors.

Corresponding: elena.mitsi@paediatrics.ox.ac.uk, daniela.ferreira@paediatrics.ox.ac.uk

ABSTRACT

Respiratory mucosal immunity induced by vaccination is vital for protection from coronavirus infection in animal models. In humans, SARS-CoV-2 immunity has been studied extensively in blood. However, the capacity of peripheral vaccination to generate sustained humoral and cellular immunity in the lung mucosa, and how this is influenced by prior SARS-CoV-2 infection, is unknown. Bronchoalveolar lavage samples obtained from vaccinated donors with or without prior infection revealed enrichment of spike-specific antibodies, class-switched memory B cells and T cells in the lung mucosa compared to the periphery in the setting of hybrid immunity, whereas in the context of vaccination alone, local anti-viral immunity was limited to antibody responses. Spike-specific T cells persisted in the lung mucosa for up to 5 months post-vaccination and multi-specific T cell responses were detected at least up to 11 months post-infection. Thus, durable lung mucosal immunity against SARS-CoV-2 seen after hybrid exposure cannot be achieved by peripheral vaccination alone, supporting the need for vaccines targeting the airways.

Key words: human lung mucosa, hybrid immunity, SARS-CoV-2 vaccination, airway memory T cells

1 INTRODUCTION

2 Respiratory mucosal surfaces are the primary site of interaction between SARS-CoV-2 and
3 the immune system. Mucosal antibodies and tissue-resident memory T (TRM) and B cells
4 provide frontline early responses, contributing to protection against the establishment of
5 viral infection following previous viral exposure or vaccination^{1, 2 3}. Animal studies of
6 influenza virus infection have shown that development of antigen-specific resident memory
7 B cells in the lung produces local IgG and IgA with enhanced cross-recognition of variants⁴
8 and correlates with protection against reinfection in mice^{5, 6}. Additionally, studies of
9 respiratory viral infections in animals and human controlled challenge have highlighted the
10 essential role of local tissue-memory T cells in promoting immunity against influenza and
11 respiratory syncytial virus (RSV) mediated, at least in part, by rapid IFN- γ production^{7, 8, 9, 10,}
12 ^{11, 12}. Interestingly, in a murine model of SARS-1 and MERS coronavirus infection, protection
13 was attributed to the induction of CD4⁺ T cells in the airway¹³.

14 The difficulty accessing human mucosal sites, particularly the lower airways, and the low
15 recovery of fluid and cell yield, have hindered the study of local immunity to respiratory
16 pathogens. Most of the human studies have assessed antibody and T cell responses to SARS-
17 CoV-2 in blood, which is often not reflective of the responses in the airways. However, we
18 and others have demonstrated the presence of pre-existing T cells that recognize SARS-CoV-
19 2 in the lower airways or oropharyngeal lymphoid tissue of unexposed individuals
20 respectively^{14, 15}, likely induced by seasonal coronavirus infections. Presence of SARS-CoV-2
21 specific T cells were also reported in human nasal¹⁶, lung mucosa and lung-associated lymph
22 nodes following SARS-CoV-2 infection^{17, 18}. Furthermore, increased numbers of global CD4⁺
23 and CD8⁺ in the airways of SARS-CoV-2-infected patients were associated with reduced
24 disease severity^{19, 20}. It has also been reported that spike-specific memory B cells were
25 enriched in the lungs and associated lymph nodes of convalescent organ donors¹⁸ and that
26 SARS-CoV-2-binding IgA antibodies are produced more rapidly than IgG and can be detected
27 in the serum and saliva of COVID-19 patients up to 40 days post onset of symptoms^{21, 22, 23,}
28 ²⁴.

29 Recent animal work with different SARS-CoV-2 vaccine formulations showed the need for
30 mucosal immunisation to generate resident virus-specific B and T cells in the lungs and
31 confirmed the importance of localised mucosal immunity in control of infection^{17, 25, 26, 27}.
32 Human studies that described the effect of peripheral SARS-CoV-2 vaccines on the

respiratory mucosa are conflicting. While nasal and salivary IgA responses²⁸, as well as CD4⁺ and CD8⁺ T_{RM} were detected in the nasal mucosa²⁹ of vaccinated individuals without history of SARS-CoV-2 infection²⁸, other studies reported minimal or lack of humoral and T cell responses in nasal and lung mucosa following peripheral vaccination only^{17, 30}. However, such responses were detected in convalescent donors or after breakthrough infection^{17, 18, 30, 31}.

Further studies are needed to better characterise immune responses in the airways after infection and/or vaccination and dissect out the influence of hybrid immunity, vaccine type, disease severity, and particularly time since vaccination or infection to address persistence of mucosal immunity. Using bronchoalveolar lavage (BAL) samples collected before the onset of the COVID-19 pandemic, we have previously demonstrated that SARS-CoV-2-cross-reactive T cells can reside in human airways¹⁴. Here, we tested BAL samples and paired blood from vaccinated donors with or without prior SARS-CoV-2 infection and pre-pandemic control samples. We examined the presence of peripheral and mucosal antibodies and virus-specific B and T cell responses. Spike-specific B cells were detected in the airways of individuals exposed to SARS-CoV-2 up to 11 months previously and virus-specific CD4⁺ and CD8⁺ T cells were more abundant in this group compared to vaccinated uninfected individuals. A better understanding of the breath and longevity of adaptive immunity to SARS-CoV2 in the airways will allow us to harness protective mucosal immunity to inform next generation of SARS-CoV-2 vaccines with potential to block infection and population transmission.

54

55 RESULTS

56 Characteristics of study groups

To assess humoral and cellular immune responses in the lung mucosa and blood following SARS-CoV-2 vaccination and hybrid immunity, we collected bronchoalveolar lavage (BAL) fluid and paired blood samples from 7 vaccinees with no history or evidence of SARS-CoV-2 infection (naïve, vaccinated group) and 15 vaccinees who had serologically-confirmed asymptomatic infection or experienced symptomatic infection between 2 to 11 months (56 – 333 days) prior to receiving SARS-CoV-2 vaccination. Vaccinated individuals with asymptomatic and symptomatic infection were combined in one ‘hybrid immunity’ group, due to the lack of obvious difference in immune responses to SARS-CoV-2 antigens. All

65 vaccinated individuals received two doses of either mRNA or adenoviral vector vaccine. We
66 also included a pre-pandemic group (n=11) of unexposed, unvaccinated individuals as
67 controls (Figure 1A). Table 1 summarizes the demographic characteristics of the three study
68 groups and the time of sample collection in relation to infection or last vaccination.

69

70 **Airway antibody responses following hybrid immunity or vaccination alone**

71 Levels of circulating and mucosal antibodies against spike (S), receptor binding domain
72 (RBD) and nucleocapsid (N) protein were measured in serum and BAL samples in all three
73 study groups. Antibody responses to N protein (non-vaccine protein) were used to confirm
74 absence of past infection in the vaccinated cohort and classify the groups. Limit of sensitivity
75 (LOS) was set as median + 2 x standard deviation (SD) of the results in unexposed (pre-
76 pandemic) donors. As expected, anti-N IgG was below or near the LOS in the naïve
77 vaccinated group, whereas in the infected vaccinated group, it was detected in all
78 individuals (15/15) in serum and in 47% (7/15) in the BAL fluid (Extended Data Figure 1A and
79 B).

80 SARS-CoV-2 vaccination elicited robust systemic IgG responses to both S and RBD protein,
81 with levels being more pronounced in the infected vaccinated group (3.4-fold and 3.3-fold
82 median increase of anti-S and anti-RBD IgG compared to naïve vaccinated group,
83 respectively) (p=0.039) and p=0.11, respectively) (Figure 1B and C). Such systemic antibody
84 differences as a result of hybrid immunity have been extensively demonstrated in large
85 cohort vaccination studies^{32, 33}. High levels of anti-S and -RBD IgG were also detected in the
86 BAL fluid of SARS-CoV-2 vaccinees. Importantly, anti-S and anti-RBD IgG levels in the lung
87 were also significantly elevated in the hybrid immunity group compared to the naïve
88 vaccinated group (8.2-fold and 9.4-fold increase for S and RBD, respectively) (p=0.024 and
89 p=0.014, respectively) (Figure 1D and E).

90 As IgA plays a crucial role in the antiviral immune defence in mucosal surfaces^{34, 35}, IgA
91 responses against SARS-CoV-2 proteins were also assessed in BAL samples. In the naïve
92 vaccinated group, mucosal IgA levels against S, RBD and N did not differ from the control
93 group. However, the infected vaccinated group had significantly greater mucosal anti-S IgA
94 (2.5-fold increase from control, p=0.014) and a trend to higher anti-RBD IgA (Figure 1F and
95 G), whereas the majority had non- detectable anti-N IgA levels in BAL (Extended Data Figure
96 1C).

Vaccine-induced antibody responses to S protein demonstrated a strong correlation between serum and BAL for IgG and slightly less so for IgA (Extended Data figure 1D and E).

99

100

Presence of SARS-CoV-2 specific memory B cells in the lung following hybrid immunity

Memory B cells are critical for long-term humoral immunity. To identify SARS-CoV-2 specific memory B cells (MBCs), fluorescently labelled S, RBD and N proteins were used to assay PBMCs and lung leukocytes (Figure 2A) (see gating strategy, Extended Data Figure 2A). As expected, and in line with the antibody responses, only vaccinees who had previously been exposed to viral nucleoprotein through infection had detectable N-specific MBCs in the blood. By contrast, both naïve vaccinated and infected vaccinated individuals had circulating S- and RBD-specific MBCs above the background staining threshold (set as median + 2 x SD of pre-pandemic levels).

B cells are an underrepresented cell population in the lung mucosa; their presence in the lung is usually associated with infection or chronic inflammation³⁶. Although data on anti-viral B cell immunity in human respiratory mucosa are scarce, murine model studies of influenza infection demonstrated the generation of flu-specific memory B cells in the lung following influenza infection that were able to produce more antibodies with enhanced potential to recognise viral variants^{4, 5, 6}. In this study, the small number of B cells in the BAL samples allowed the assessment of SARS-CoV-2 specific MBCs only in the hybrid immunity group. The frequencies of S-, RBD- and N-specific MBCs were greater in the lung mucosa of infected vaccinated individuals compared to pre-pandemic controls (median 5.5% vs 0.08% for S, 2.88% vs 0.06% for RBD and 1.69% vs 0.06% for N-specific responses (p=0.0004, p=0.016 and p=0.016, respectively) (Figure 2E-2G). Paired sample comparison of the frequencies of circulating and mucosally detected anti-viral MBCs in the infected vaccinated group revealed enrichment of S- and RBD-specific MBCs in the lung mucosa. The median frequencies of S- and RBD-specific MBCs were 2.1-fold (p=0.0078) and 3.8-fold (p=0.062) higher in the BAL compared to PBMC sample from the same donors (Figure 2H). We detected that in the lung mucosa memory B cells were mainly class-switched MBCs, whereas paired blood samples had a significantly increased proportion of unswitched MBCs cells (Figure 2I).

We also stratified the infected vaccinated group based on the vaccine they received. Despite the small sample size, mRNA vaccinated individuals exhibited 1.8-fold higher frequency of circulating S-specific MBCs compared to ChAdOX1_S recipients ($p=0.037$), and a trend to higher RBD-specific B cells (Extended Data Figure 2B). In lung mucosa, a similar trend was observed for S-specific MBCs levels (Extended Data Figure 2C), but low cell yields hindered a robust analysis.

Robust T cells responses in the lung mucosa after infection and vaccination but not vaccination alone

Circulating and tissue resident memory (T_{RM}) T cells are important in constraining viral spread and protect against severe disease when neutralising antibodies fail to confer sterilising immunity^{37, 38, 39}. Moreover, we showed that T cells targeting the early expressed replication transcription complex (RTC: NSP7,12,13) are selectively associated with infection being aborted before detection by PCR or seroconversion and can be detected in pre-pandemic blood and lung samples^{14, 40}. Therefore, we examined T cell responses in blood and BAL samples following vaccination alone or infection and vaccination in blood and paired BAL samples.

The frequencies of circulating and lower airway $CD4^+$ and $CD8^+$ T cells were measured based on the expression of activation-induced markers (AIM assay) after stimulation with SARS-CoV-2 peptides (for full gating strategy see Extended Data figure 3A) and were compared to pre-existing cross-reactive responses detectable using the same assays in cryopreserved pre-pandemic BAL samples. BAL samples were further divided by the expression of prototypic tissue residency markers (CD69/CD103 co-expression for $CD8$ and CD69/CD49a expression for $CD4$ /CD49a into T_{RM} and recirculating T cells. As reported by others^{41, 42, 43}, SARS-CoV-2 vaccination alone induced notable S-specific $CD4^+$ and $CD8^+$ T cell responses in the circulation when compared to pre-pandemic controls (Figure 3B and 3C). In the infected vaccinated group, the frequency of circulating S-specific $CD4^+$ and $CD8^+$ T cells tended to be higher than the naïve vaccinated group (1.8-fold and 4.8-fold increase, respectively). Despite the induction of T cell immunity systemically, vaccination alone did not elicit S-specific T cell responses that were significantly greater than those in pre-pandemic samples within the global (Figure 3D and 3E) or T_{RM} lung compartment (Figure 3F and 3G).

As opposed to vaccination alone, BAL samples from those who acquired hybrid immunity exhibited greater anti-Spike T cell responses than either the pre-pandemic or naïve vaccinated group (Figure 3D-3G). Within the global T cell population, the frequency of S-specific CD4⁺ and CD8⁺ T cells increased by 2.8-fold and 5.3-fold higher in the infected, vaccinated group compared to the naïve, vaccinated group (p=0.048 and p=0.012, respectively) (Figure 3D and 3E). A similar profile was observed in the T_{RM} T cell compartment, with S-specific CD4⁺ and CD8⁺ T cell frequencies being 2.8-fold and 4.8-fold greater, respectively, in the hybrid immunity group compared to naïve vaccinated group (p=0.05 and p=0.017, respectively) (Figure 3F and 3G). In addition, within the global T cell population, the frequencies of S-specific CD4⁺ and CD8⁺ T cells were substantially higher in BAL than in paired blood from infected vaccinated individuals (median 2.45% vs 0.62% of S-specific CD4⁺ T cells and median 1.84% vs 0.24% of S-specific CD8⁺ T in BAL and paired blood of infected, vaccinated individual, respectively) (p=0.0005 and p=0.0002, respectively) (Figure 3H and 3I). In the naïve, vaccinated group the frequency of S-specific CD4⁺ but not CD8⁺ T cells was slightly higher in BAL than PBMCs (median 0.89% vs 0.35% in BAL and paired blood, respectively).

In agreement with large vaccination studies^{44, 45}, we observed that adenoviral vector vaccine tended to induce increased frequency of S-specific T cells in the periphery compared to mRNA vaccines. The tendency of the adenoviral vector vaccine to induce stronger T cell immunity was also observed in the lower airways, with 3.3-fold and 2.5-fold higher S-specific CD4⁺ and CD8⁺ T cell responses when compared to RNA vaccination (Extended Data Figure 3B-C).

We also examined T cell specificities for non-vaccine included SARS-CoV-2 structural proteins (N and membrane [M]) and non-structural proteins (NSP-7, NSP-12 and NSP-13 pool, representative of the core replication-transcription complex [RTC]) in blood and BAL (Extended Data Figure 3D-E and Figure 4). As expected, the frequencies of circulating N- and M-specific CD4⁺ and CD8⁺ T cells were significantly higher than in pre-pandemics only in the hybrid immunity group, as those vaccinees had a past SARS-CoV-2 infection (Figure 4A and 4B). In the case of RTC-specific T cells, their frequency did not differ amongst groups, as SARS-CoV-2 cross-reactive CD4⁺ and CD8⁺ T cell responses were detected systemically in 3

out 8 pre-pandemic controls, in line with previous studies^{14, 40, 46}. In BAL samples, the frequency of the aforementioned T cell specificities was tested in a subset of pre-pandemic and infected, vaccinated individuals based on cell number availability. Interestingly, the hybrid immunity group had, or tended to have, higher N- and M- and RCT-specific T cell responses within the global and TRM T cell compartment in BAL samples compared to levels detected in pre-pandemic controls (Figure 4C-4F). In addition, these SARS-CoV-2 specific CD4⁺ and CD8⁺ T cell responses were enriched in the lower airways compared to the periphery (Figure 4G and 4H).

The hierarchy of SARS-CoV-2 antigen recognition by circulating and lower airway T cells of each distinct peptide pool (S, N, M and RTC) was analysed in a subset of 8 infected vaccinated individuals (Extended Data Figure 3D-E). The antigen recognition profile differed between systemic and airway localised T cells, and between T cell subsets. SARS-CoV-2 specific CD4⁺ T cells were largely dominated by S-specific CD4⁺ T cells in the periphery and lung mucosa, however in lower airway they were enriched with additional T cell specificities (Extended Data figure 3D). In the case of SARS-CoV-2 CD8⁺ T cells, their antigen recognition profile was more diverse in both sites, with S-specific CD8⁺ T cells being apparent but not dominant (Extended Data figure 3E).

Longevity of antibody and T cells responses in lung mucosa following vaccination alone or hybrid immunity

To assess the longevity of vaccine-induced SARS-CoV-2 immune memory in the lung mucosa following vaccination and hybrid immunity, antibody and T cell responses assessed in BAL and paired blood of naïve, vaccinated and infected vaccinated individuals were plotted in association with time post the 2nd vaccine dose (which was 2-11 months after any known infection dates). Levels of circulating anti-S and anti-RBD IgG were negatively correlated with time post-vaccination in the naïve vaccinated but not the infected vaccinated group, implying quicker antibody decay in the naïve vaccinated donors (Figure 5A). In the lung mucosa, anti-S and anti-RBD IgG levels exhibited similar rates of decay between the two vaccinated groups (Figure 5B). On the other hand, levels of anti-S and RBD IgA in BAL were detectable only following hybrid immunity but they quickly reached pre-pandemic levels (at 5-months post-vaccination, Figure 4C). This result is in agreement with previous studies in

convalescent patients that reported short-lived IgA-mediated immunity at mucosal sites^{21, 47}.

Circulating and lower-airway S-specific T cell frequencies were also plotted in association with time post-vaccination in both vaccinated groups. In blood, numbers of S-specific CD4⁺ and CD8⁺ T cells declined over time in the infected vaccinated group and at 5-months post-vaccination reached the frequencies induced by vaccination alone (Figure 6A). On the other hand, S-specific T cell responses were better sustained in the lung mucosa following hybrid immunity. Despite a trend of negative association with time post-vaccination, S-specific CD4⁺ T cell responses were detectable from the lung mucosa of infected vaccinated individuals for over 5-months post vaccination. Lower-airway S-specific CD8⁺ T cells did not associate negatively with time, suggesting they remained at stable levels throughout the period of 5-months post vaccination (Figure 6B and 6C). The human lung also retained partial immune memory to SARS-CoV-2 over a year post infection. Despite decline over time, T cell specificities not affected by SARS-CoV-2 vaccination, such as M-, N- and RTC-specific CD4⁺ and CD8⁺ T cells, were detectable in various frequencies between 6 to 18 months post infection (Figure 6D), rendering these conserved SARS-CoV-2 proteins as potential vaccine targets.

DISCUSSION

Despite high SARS-CoV-2 seroprevalence globally by either vaccination or infection, regular waves continue to cause breakthrough infections. Immunological memory to SARS-CoV-2 in the respiratory mucosa following vaccination, infection and hybrid immunity is not well understood. Protective mucosal immunity could be harnessed for the development of vaccines specifically targeting protection against airway infection to block transmission of the virus in the population.

Here, we assessed the potential of peripheral SARS-CoV-2 vaccination to induce anti-viral immune memory in the human lung mucosa and whether a prior infection would influence the immunological outcome. We found that following SARS-CoV-2 vaccination alone the lung mucosa was enriched with spike IgG, but levels were increased and accompanied by

mucosal IgA in the setting of hybrid immunity. Importantly, homologous parenteral SARS-CoV-2 vaccination (mRNA or adenoviral vector vaccine) did not seed the human lung with tissue-residing spike-specific T cells, despite the induction of notable T cell responses in the circulation. Compared to SARS-CoV-2 vaccination alone, hybrid immunity resulted in considerably higher humoral and cellular immune responses against the vaccine antigens in the periphery. In contrast to vaccination alone, hybrid immunity generated robust and persistent spike-specific T cell immunity in the human lung mucosa, complemented with local MBC and T cell responses against additional SARS-CoV-2 antigens. A long-lived, airway-compartmentalised B and T cell reservoir in the lung mucosa may confer better recognition of Omicron sublineages and future variants and protect against severe disease, supporting the need for vaccines specifically targeting the airways.

In line with others^{17, 31}, our results indicate that following vaccination alone, SARS-CoV-2 immunity in the respiratory mucosa is limited to humoral immunity, with IgG dominating over IgA titres against the vaccine-antigens. Induction of both anti-Spike IgG and IgA was more efficient in the lung mucosa of vaccinated individuals with prior infection. The strong correlation observed between anti-S IgG in serum and BAL samples supports the notion that systemic antibodies elicited by vaccination transudate to the respiratory mucosa, as previous vaccination studies have reported^{48, 49}. Despite the key role of antibodies in neutralising the virus at the respiratory mucosa- the primary site of infection, local humoral immunity wanes quickly²¹ making individuals more susceptible to immune escape by Omicron sublineages and future variants¹⁷. In addition, findings from other respiratory infection and vaccination studies indicate that higher levels of antibodies are required in the nasal mucosa to protect against local infection compared to levels required in blood to protect against invasive disease⁵⁰. However, the finding of class-switched memory B cells enriched in the lung mucosa raises the possibility they produce a repertoire of antibodies better able to cross-recognise variants, as shown in other infections⁴. Mucosal antibodies may also harness local lung cells such as NK cells and phagocytes for non-neutralising Fc-dependent cellular immunity.

Booster parenteral vaccination is required to enhance waning humoral immunity, but the frequency and intensity of robust systemic T-cell responses is not boosted by the additional

vaccination⁵¹. Hybrid immunity elicits considerably high humoral and cellular responses in the periphery, which exceed the immune responses induced solely by vaccination^{32, 52, 53}. Studying the human lung mucosa, we provide the first evidence, to our knowledge, that hybrid immunity, contrary to SARS-CoV-2 immunisation alone, can generate robust, broader, and long-lived anti-viral immune responses in the lower airways. In line with other studies^{17, 18}, the intensity of S-specific B and T cell responses were enriched in the lung mucosa compared to the periphery and similarly, enriched B and T cells responses were detected for other SARS-CoV-2 antigens. These lower-airway localised B and T cells reservoirs were long-lived. Hence using more comprehensive analysis of T cell specificities, we demonstrated that lower airway T cell immunity against SARS-CoV-2 can be sustained for over a year post the initial exposure to the pathogen. In studies of other respiratory viruses, lung localised, tissue-residing B and T cells associate with protection in mouse models of influenza^{5, 54} and RSV infection¹⁰. In human challenge models of influenza and RSV infection, enrichment of CD4⁺ and CD8⁺ T_{RM} cells in the airways was associated with mitigated respiratory symptoms, viral control, and reduced disease severity^{12, 55}. The prolonged memory together with the ability of T cells to better recognise more conserved parts of SARS-CoV-2, support the utility of developing multi-specific mucosally-administered vaccines that could boost tissue localised and resident memory T and B cells in the lung. Preclinical studies of SARS-CoV-2 have demonstrated that intranasal vaccination decreases viral shedding and transmission relative to parenteral vaccines^{27, 56, 57}. In addition, the combined approach of systemic priming SARS-CoV-2 vaccination followed by intranasal boosting with either adenovirus vectored vaccines or an adjuvanted Spike vaccine elicited both systemic and protective mucosal immunity with cross-reactive properties^{58, 59}. In humans, there are limited data on the immunogenicity of SARS-CoV-2 vaccines that target the airways, focusing mainly on humoral immunity⁶⁰.

Our study has limitations. Due to the invasive nature of the bronchoscopy procedure, we were not able to recruit a large cohort of study participants. In addition, the fast roll out and uptake of COVID-19 vaccine programme in the UK hindered the recruitment of convalescent unvaccinated individuals. The low BAL cell yields restricted the analysis of other T cell specificities to selected SARS-CoV-2 proteins and did not allow the assessment of vaccine-induced memory B cells in the lung mucosa of infection naïve individuals. Given the inability

of SARS-CoV-2 parenteral immunisation to generate tissue-localised T cell immunity, it is less likely that S-specific memory B cells will be present in the lung mucosa following vaccination. Although, we were able to detect and characterise T cell specificities for over a year post infection and up to 6 months post vaccination, future longitudinal studies are needed to fully understand the long-term impact of airway localised T and B cell immunity in SARS-CoV-2 protection.

Overall, our data suggest robust lung mucosal immunity against SARS-CoV-2 can be better achieved through hybrid immunity, as opposed to peripheral vaccination alone. Vaccines that induce airway localised memory T and B cells may provide broader long-term protection at the site of infection. Thus, vaccination approaches that combine systemic and mucosal immunisation could reduce virus transmission and re-infection cases.

METHODS

Study design and cohorts

This was a cross-sectional study, which included a cohort of SARS-CoV-2 vaccinated individuals (n=22), who had received two doses of mRNA or the ChAdOx1_S adenoviral vector vaccine. A subset of them had experienced PCR-confirmed symptomatic infection (n=12) or serologically confirmed asymptomatic infection (n=3), referred to the group of infected and vaccinated individuals (hybrid immunity) (n=15), whereas the remaining vaccinees had not experienced SARS-CoV-2 infection (vaccinated, n=7). BAL samples were obtained through research bronchoscopy 1 to 6 months (23-186 days) after the 2nd vaccine dose and 7 to 19 months (201 -570 days) after symptoms onset for those who had experienced COVID-19. These COVID-19 convalescent individuals had been admitted to hospital between April 2020 to January 2021, when the ancestral SARS-CoV-2 strain was still dominant in the UK. Blood samples for sera and PBMC isolation were collected at the same day as BAL. Pre-pandemic samples from healthy, unexposed individuals (n=11), collected from 2015 to 2018, were also included into the analysis, as a control group (Figure 1A). The demographic and clinical characteristics of the 3 study groups are shown in Table 1.

Sample processing

BAL samples were processed as previously described⁶¹, cryopreserved in CTL-CryoABC medium kit (Immunospot). After thawing, alveolar macrophages were routinely separated from other non-adherent immune cell populations using an adherence step, as previously described⁶². Blood was processed for sera collection or PBMCs were isolated from heparinized blood samples using density-gradient sedimentation layered over Ficoll-Paque in SepMate tube and then cryopreserved in CTL-CryoABC medium kit (Immunospot).

ELISA for SARS-CoV-2 proteins

ELISA was used to quantify levels of IgG and IgA against Spike trimer, RBD and N in serum and BAL samples, as previously described⁶³. Briefly, 96-well plates (U bottom) were coated with 1µg/ml SARS-CoV-2 antigen and stored at 4°C overnight for at least 16h. The next day, plates were washed 3 times with PBS/0.05% Tween-20 and blocked with 2% BSA in PBS for 1h at room temperature. Sera and BAL diluted in 0.1% BSA-PBS were plated in duplicate and incubated for 2h at room temperature alongside an internal positive control (dilution of a convalescent serum) to measure plate to plate variation. For the standard curve, a pooled sera of SARS-CoV-2 infected participants was used in a two-fold serial dilution to produce either eight or nine standard points (depending on the antigen) that were assigned as arbitrary units. Goat anti-human IgG (γ-chain specific, A9544, Millipore-Sigma) or IgA (α-chain specific, A9669, Millipore-Sigma) conjugated to alkaline phosphatase was used as secondary antibody, and plates were developed by adding 4-nitrophenyl phosphate in diethanolamine substrate buffer. Optical densities were measured using an Omega microplate reader at 405nm. Blank corrected samples and standard values were plotted using the 4-Parameter logistic model (Gen5 v3.09, BioTek).

B cells immunophenotyping and detection of SARS-CoV-2 specific B cells

Cryopreserved BAL cells and PBMCs were used for detection of SARS-CoV-2 specific B cells in lower airways and blood, respectively. Biotinylated tetrameric S, RBD and N protein were individually labelled with different streptavidin conjugates at 4°C for 1h, as previously described⁶³. Biotinylated S and RBD were directly labelled with Streptavidin-PE (with a ratio 1:3 and 1: 5.7, respectively); with Streptavidin-BV570 (S with a ratio 1: 2.7); and Streptavidin-BV785

(RBD with a ratio 1:5). Biotinylated N protein was labelled with Streptavidin-PE (with a ratio of 1:2.3) and Streptavidin-AF647 (N protein with a ratio 1: 0.5).

PBMCs and BAL cells were thawed and stained with Live/dead e506 viability dye and an antibody cocktail for surface markers for 30min in the dark, washed twice and resuspended in 200µL of PBS. Parallel samples stained with an identical panel of monoclonal antibodies (mAbs),but excluding the SARS-CoV-2 proteins (fluorescence minus one [FMO] controls), were used as controls for nonspecific binding. All samples were acquired on an Aurora cytometer (Cytek Biosciences) and analysed with Flowjo software version 10 (Treestar). The flow-cytometry panel of mAbs used to phenotype global and antigen-specific subsets can be seen in Supplementary Table 1.

The frequency of antigen-specific B cells was calculated within the fraction of MBCs (CD19⁺CD27⁺, excluding the naïve IgD⁺CD27⁻ and the double negative IgG⁺CD27⁻ fractions, see gating strategy (Extended Data Figure 2A). For phenotypic analysis of spike-, RBD-, and N-specific B cells, a sufficient magnitude of responses (≥50 cells in the relevant parent gate) was required.

Activation-induced markers (AIM) T cell assay

Mononuclear BAL cells (1 x 10⁵ cells per well) and PBMCs (1 x 10⁶ cells per well) were seeded in 96-well plates in RPMI supplemented with 1% PNS and 10% AB human serum (Merck, UK) and stimulated with SARS-CoV-2 specific peptides pools. The peptides pools used were spanning the whole Spike protein based on predicted epitopes (15-mer peptides overlapping by 10 amino acids)⁶⁴ or overlapping peptides spanning the immunogenic domains of the SARS-CoV-2 N (Prot_N) and M (Prot_M) purchased from Miltenyi Biotec⁶³ or combined pools spanning SARS-CoV-2 NSP7, NSP12 and NSP13 proteins (15-mer peptides overlapping by 10 amino acids) of the ancestral SARS-CoV-2 strain^{14, 65}. Prior to the peptide addition, cells were blocked with 0.5µg/ml of anti-CD40 mAb (Miltenyi Biotec) for 15min at 37°C. A stimulation with an equimolar amount of DMSO was performed as a negative control and Staphylococcal enterotoxin B (SEB, 2 µg/mL) was included as a positive control. The following day cells were harvested from plates, washed and stained for surface markers (Supplemental table 2 and 3).

AIM⁺ CD4⁺ T cells were identified as CD40L⁺OX40⁺, 4-1BB⁺OX40⁺, 4-1BB⁺CD40L⁺ subsets, and the CD40L⁺OX40⁺ combination was used to quantify SARS-CoV-2 specific CD4⁺ T cells

frequency. SARS-CoV-2 specific CD8⁺ T cells were identified as 4-1BB⁺CD25⁺. Antigen-specific CD4⁺ and CD8⁺ T cells were measured and presented as DMSO background–subtracted data.

Statistical analysis

Participant characteristics were summarised as n, median (interquartile range) or frequency (percentage). Chi-squared test and Fisher's exact test were conducted to identify any significant changes in categorical variables. Non-parametric Wilcoxon paired tests and Mann-Whitney tests were conducted to compare quantitative data within the same group or between two groups, respectively. In addition, Kruskal-Wallis rank sum test with Dunn's correction were performed to compare quantitative data amongst groups (three groups comparison). All tests were two-sided with an α level of 0.05. To explore the association between time after infection and vaccination, we employed a linear regression model. Data were analysed in R software version 4.0.3 (R Foundation for Statistical Computing, Vienna, Austria) or Graphpad Prism version 9.0.

Ethics statement

All volunteers gave written informed consent and research was conducted in compliance with all relevant ethical regulations. Ethical approval was given by the NorthWest National Health Service Research Ethics Committee (REC no. 18/NW/0481 and Human Tissue licensing no. 12548).

Acknowledgements

We thank all the patients and healthy volunteers who participated in the present study and all the clinical staff who helped with recruitment and sample collection. The study was financially supported by EPSRC grant (no. EP/W016389/1) awarded to E.M and D.M.F and a Centre of Excellence in Infectious Diseases Research (CEIDR) pump-priming grant. Collection of pre-pandemic clinical samples was supported by the Bill and Melinda Gates Foundation (grant no. OPP1117728) and the UK Medical Research Council (grant no. M011569/1) awarded to D.M.F. The production of peptide pools has been funded or in part with federal funds from the National Institutes of Health, Contract No. 75N9301900065 to A.S, D.W. M.K.M. is supported by Wellcome Trust Investigator Award (no. 214191/Z/18/Z) and CRUK Immunology grant (no.26603).

443

444 **Authors contribution**

445 E.M, M.O.D, M.K.M and D.M.F conceived and designed the study. A.H.W and M.F recruited
446 and consented study participants. A.H.W, M.F, R.R and A.M.C obtained human samples.
447 E.M, J.R, J.H and CS processed samples. E.M, M.O.D, J.R, J.H, O.O and T.L generated and
448 analysed the data. E.M. M.O.D, M.K.M and D.M.F interpreted data. E.M, J.R and B.U
449 developed the assays. S.J.D, D.W and A.S provided material for the assays. E.M and M.O.D
450 prepared the manuscript. All authors provided critical input into the manuscript.

451

452 **Declaration of Interest**

453 A.S. is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress,
454 Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax,
455 Gerson Lehrman Group and Guggenheim. LJL has filed for patent protection for various
456 aspects of T cell epitope and vaccine design work.

457

REFERENCES

- 458 1. Zheng, M.Z.M. & Wakim, L.M. Tissue resident memory T cells in the respiratory tract.
459 *Mucosal Immunology* (2021).
460
- 461 2. Son, Y.M. & Sun, J. Co-Ordination of Mucosal B Cell and CD8 T Cell Memory by
462 Tissue-Resident CD4 Helper T Cells. *Cells* **10** (2021).
463
- 464 3. Lee, C.M. & Oh, J.E. Resident Memory B Cells in Barrier Tissues. *Front Immunol* **13**,
465 953088 (2022).
466
- 467 4. Adachi, Y. *et al.* Distinct germinal center selection at local sites shapes memory B cell
468 response to viral escape. *J Exp Med* **212**, 1709-1723 (2015).
469
- 470 5. Allie, S.R. *et al.* The establishment of resident memory B cells in the lung requires
471 local antigen encounter. *Nature Immunology* **20**, 97-108 (2019).
472
- 473 6. Onodera, T. *et al.* Memory B cells in the lung participate in protective humoral
474 immune responses to pulmonary influenza virus reinfection. *Proc Natl Acad Sci U S A*
475 **109**, 2485-2490 (2012).
476
- 477 7. Wu, T. *et al.* Lung-resident memory CD8 T cells (TRM) are indispensable for optimal
478 cross-protection against pulmonary virus infection. *J Leukoc Biol* **95**, 215-224 (2014).

- 479
- 480 8. Pizzolla, A. *et al.* Resident memory CD8(+) T cells in the upper respiratory tract
- 481 prevent pulmonary influenza virus infection. *Sci Immunol* **2** (2017).
- 482
- 483 9. Turner, D.L. *et al.* Lung niches for the generation and maintenance of tissue-resident
- 484 memory T cells. *Mucosal Immunol* **7**, 501-510 (2014).
- 485
- 486 10. Kinnear, E. *et al.* Airway T cells protect against RSV infection in the absence of
- 487 antibody. *Mucosal Immunol* **11**, 249-256 (2018).
- 488
- 489 11. Luangrath, M.A., Schmidt, M.E., Hartwig, S.M. & Varga, S.M. Tissue-Resident
- 490 Memory T Cells in the Lungs Protect against Acute Respiratory Syncytial Virus
- 491 Infection. *Immunohorizons* **5**, 59-69 (2021).
- 492
- 493 12. Jozwik, A. *et al.* RSV-specific airway resident memory CD8+ T cells and differential
- 494 disease severity after experimental human infection. *Nat Commun* **6**, 10224 (2015).
- 495
- 496 13. Zhao, J. *et al.* Airway Memory CD4(+) T Cells Mediate Protective Immunity against
- 497 Emerging Respiratory Coronaviruses. *Immunity* **44**, 1379-1391 (2016).
- 498
- 499 14. Diniz, M.O. *et al.* Airway-resident T cells from unexposed individuals cross-recognize
- 500 SARS-CoV-2. *Nat Immunol* **23**, 1324-1329 (2022).
- 501
- 502 15. Niessl, J. *et al.* Identification of resident memory CD8(+) T cells with functional
- 503 specificity for SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. *Sci Immunol*
- 504 **6**, eabk0894 (2021).
- 505
- 506 16. Roukens, A.H.E. *et al.* Prolonged activation of nasal immune cell populations and
- 507 development of tissue-resident SARS-CoV-2-specific CD8+ T cell responses following
- 508 COVID-19. *Nature Immunology* **23**, 23-32 (2022).
- 509
- 510 17. Tang, J. *et al.* Respiratory mucosal immunity against SARS-CoV-2 after mRNA
- 511 vaccination. *Sci Immunol* **7**, eadd4853 (2022).
- 512
- 513 18. Poon, M.M.L. *et al.* SARS-CoV-2 infection generates tissue-localized immunological
- 514 memory in humans. *Sci Immunol* **6**, eabl9105 (2021).
- 515
- 516 19. Szabo, P.A. *et al.* Longitudinal profiling of respiratory and systemic immune
- 517 responses reveals myeloid cell-driven lung inflammation in severe COVID-19.
- 518 *Immunity* **54**, 797-814 e796 (2021).
- 519
- 520 20. Liao, M. *et al.* Single-cell landscape of bronchoalveolar immune cells in patients with
- 521 COVID-19. *Nat Med* **26**, 842-844 (2020).
- 522
- 523 21. Sterlin, D. *et al.* IgA dominates the early neutralizing antibody response to SARS-CoV-
- 524 2. *Science Translational Medicine* **13**, eabd2223 (2021).
- 525

- 526 22. Yu, H.Q. *et al.* Distinct features of SARS-CoV-2-specific IgA response in COVID-19
527 patients. *Eur Respir J* **56** (2020).
528
- 529 23. Ma, H. *et al.* Serum IgA, IgM, and IgG responses in COVID-19. *Cellular & Molecular*
530 *Immunology* **17**, 773-775 (2020).
531
- 532 24. Seow, J. *et al.* Longitudinal evaluation and decline of antibody responses in SARS-
533 CoV-2 infection. *medRxiv*, 2020.2007.2009.20148429 (2020).
534
- 535 25. Oh, J.E. *et al.* Intranasal priming induces local lung-resident B cell populations that
536 secrete protective mucosal antiviral IgA. *Sci Immunol* **6**, eabj5129 (2021).
537
- 538 26. Afkhami, S. *et al.* Respiratory mucosal delivery of next-generation COVID-19 vaccine
539 provides robust protection against both ancestral and variant strains of SARS-CoV-2.
540 *Cell* **185**, 896-915 e819 (2022).
541
- 542 27. van Doremalen, N. *et al.* Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces
543 viral shedding after SARS-CoV-2 D614G challenge in preclinical models. *Sci Transl*
544 *Med* **13** (2021).
545
- 546 28. S, G. *et al.* Serological response to SARS-CoV-2 vaccination in multiple sclerosis
547 patients treated with fingolimod or ocrelizumab: an initial real-life experience. *J*
548 *Neurol* **269**, 39-43 (2022).
549
- 550 29. Ssemaganda, A. *et al.* Expansion of cytotoxic tissue-resident CD8+ T cells and
551 CCR6+CD161+ CD4+ T cells in the nasal mucosa following mRNA COVID-19
552 vaccination. *Nature Communications* **13**, 3357 (2022).
553
- 554 30. Lim, J.M.E. *et al.* SARS-CoV-2 breakthrough infection in vaccinees induces virus-
555 specific nasal-resident CD8+ and CD4+ T cells of broad specificity. *J Exp Med* **219**
556 (2022).
557
- 558 31. Sano, K. *et al.* SARS-CoV-2 vaccination induces mucosal antibody responses in
559 previously infected individuals. *Nature Communications* **13**, 5135 (2022).
560
- 561 32. Bates, T.A. *et al.* Vaccination before or after SARS-CoV-2 infection leads to robust
562 humoral response and antibodies that effectively neutralize variants. *Sci Immunol* **7**,
563 eabn8014 (2022).
564
- 565 33. Krammer, F. *et al.* Antibody Responses in Seropositive Persons after a Single Dose of
566 SARS-CoV-2 mRNA Vaccine. *New England Journal of Medicine* **384**, 1372-1374
567 (2021).
568
- 569 34. Sterlin, D. *et al.* IgA dominates the early neutralizing antibody response to SARS-CoV-
570 2. *Sci Transl Med* **13** (2021).
571

- 572 35. Mazanec, M.B., Coudret, C.L. & Fletcher, D.R. Intracellular neutralization of influenza
573 virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. *J Virol* **69**,
574 1339-1343 (1995).
575
- 576 36. Menon, M., Hussell, T. & Ali Shuwa, H. Regulatory B cells in respiratory health and
577 diseases. *Immunol Rev* **299**, 61-73 (2021).
578
- 579 37. Rosato, P.C., Beura, L.K. & Masopust, D. Tissue resident memory T cells and viral
580 immunity. *Curr Opin Virol* **22**, 44-50 (2017).
581
- 582 38. Son, Y.M. *et al.* Tissue-resident CD4(+) T helper cells assist the development of
583 protective respiratory B and CD8(+) T cell memory responses. *Sci Immunol* **6** (2021).
584
- 585 39. Pruner, K.B. & Pepper, M. Local memory CD4 T cell niches in respiratory viral
586 infection. *J Exp Med* **218** (2021).
587
- 588 40. Swadling, L. *et al.* Pre-existing polymerase-specific T cells expand in abortive
589 seronegative SARS-CoV-2. *Nature* **601**, 110-117 (2022).
590
- 591 41. Ewer, K.J. *et al.* T cell and antibody responses induced by a single dose of ChAdOx1
592 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. *Nature Medicine* **27**, 270-278
593 (2021).
594
- 595 42. Moss, P. The T cell immune response against SARS-CoV-2. *Nature Immunology* **23**,
596 186-193 (2022).
597
- 598 43. Sahin, U. *et al.* BNT162b2 vaccine induces neutralizing antibodies and poly-specific T
599 cells in humans. *Nature* **595**, 572-577 (2021).
600
- 601 44. Heinz, F.X. & Stiasny, K. Distinguishing features of current COVID-19 vaccines:
602 knowns and unknowns of antigen presentation and modes of action. *npj Vaccines* **6**,
603 104 (2021).
604
- 605 45. Lewis, D. Mix-and-match COVID vaccines: the case is growing, but questions remain.
606 *Nature* **595**, 344-345 (2021).
607
- 608 46. Grifoni, A. *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans
609 with COVID-19 Disease and Unexposed Individuals. *Cell* (2020).
610
- 611 47. Pang, N.Y.-L., Pang, A.S.-R., Chow, V.T. & Wang, D.-Y. Understanding neutralising
612 antibodies against SARS-CoV-2 and their implications in clinical practice. *Military*
613 *Medical Research* **8**, 47 (2021).
614
- 615 48. Mitsi, E. *et al.* PCV13 induced IgG responses in serum associate with serotype-
616 specific IgG in the lung. *J Infect Dis* (2021).
617

- 618 49. Carniel, B.F. *et al.* Pneumococcal colonization impairs mucosal immune responses to
619 live attenuated influenza vaccine. *JCI Insight* **6** (2021).
620
- 621 50. Dagan, R. *et al.* Modeling pneumococcal nasopharyngeal acquisition as a function of
622 anticapsular serum antibody concentrations after pneumococcal conjugate vaccine
623 administration. *Vaccine* **34**, 4313-4320 (2016).
624
- 625 51. Maringer, Y. *et al.* Durable spike-specific T-cell responses after different COVID-19
626 vaccination regimens are not further enhanced by booster vaccination. *Sci Immunol*,
627 eadd3899 (2022).
628
- 629 52. Reynolds, C.J. *et al.* Prior SARS-CoV-2 infection rescues B and T cell responses to
630 variants after first vaccine dose. *Science* **372**, 1418-1423 (2021).
631
- 632 53. Crotty, S. Hybrid immunity. *Science* **372**, 1392-1393 (2021).
633
- 634 54. Teijaro, J.R. *et al.* Cutting edge: Tissue-retentive lung memory CD4 T cells mediate
635 optimal protection to respiratory virus infection. *J Immunol* **187**, 5510-5514 (2011).
636
- 637 55. Wilkinson, T.M. *et al.* Preexisting influenza-specific CD4+ T cells correlate with
638 disease protection against influenza challenge in humans. *Nat Med* **18**, 274-280
639 (2012).
640
- 641 56. Hassan, A.O. *et al.* A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower
642 Respiratory Tracts against SARS-CoV-2. *Cell* **183**, 169-184 e113 (2020).
643
- 644 57. Hassan, A.O. *et al.* A single intranasal dose of chimpanzee adenovirus-vectored
645 vaccine protects against SARS-CoV-2 infection in rhesus macaques. *Cell Rep Med* **2**,
646 100230 (2021).
647
- 648 58. Mao, T. *et al.* Unadjuvanted intranasal spike vaccine elicits protective mucosal
649 immunity against sarbecoviruses. *Science*, eabo2523 (2022).
650
- 651 59. Lapuente, D. *et al.* Protective mucosal immunity against SARS-CoV-2 after
652 heterologous systemic prime-mucosal boost immunization. *Nat Commun* **12**, 6871
653 (2021).
654
- 655 60. Madhavan, M. *et al.* Tolerability and immunogenicity of an intranasally-administered
656 adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised
657 ascending dose phase I trial. *eBioMedicine* **85** (2022).
658
- 659 61. Zaidi, S.R. *et al.* Single use and conventional bronchoscopes for Broncho alveolar
660 lavage (BAL) in research: a comparative study (NCT 02515591). *BMC Pulmonary*
661 *Medicine* **17**, 83 (2017).
662

- 663 62. Mitsi, E. *et al.* Nasal Pneumococcal Density Is Associated with Microaspiration and
664 Heightened Human Alveolar Macrophage Responsiveness to Bacterial Pathogens.
665 *Am J Respir Crit Care Med* **201**, 335-347 (2020).
666
667 63. Mitsi, E. *et al.* Streptococcus pneumoniae colonization associates with impaired
668 adaptive immune responses against SARS-CoV-2. *J Clin Invest* (2022).
669
670 64. Dan, J.M. *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months
671 after infection. *Science* **371** (2021).
672
673 65. Le Bert, N. *et al.* SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS,
674 and uninfected controls. *Nature* **584**, 457-462 (2020).
675

Table 1: Characteristics of participants

Characteristics	Controls (n=11)	Vaccinated (n=7)	Infected & Vaccinated (n=15)
Age (yr), median (IQR)	21 (19 – 24)	25 (23 – 41)	43 (20 – 52)
Female, n (%)	7 (64%)	4 (57%)	10 (67%)
Time since symptomatic infection in days, median (min – max)	n/a	n/a	273 (201 – 570)
NIH clinical score, median (IQR)	n/a	n/a	4 (3-4)
Vaccination history			
Vaccine type	n/a	BNT162b2, n=5 ChAdOx1_S, n=2	BNT162b2, n=9 Moderna, n=1 ChAdOx1_S, n=5
Time since 2 nd vaccine dose in days, median (min – max)	n/a	113 (23 – 186)	73 (23 -160)

Figure 1. Systemic and lung mucosa antibody responses following vaccination alone and hybrid immunity. A) Schematic of study groups depicting SARS-CoV-2 vaccination status, sample collection per group and immunological parameters analysed. Pre-pandemic controls (n=11), infection-naïve vaccinated individual (naïve vaccinated group, n=7) and vaccinated individuals with exposure to SARS-CoV-2 (infected vaccinated or hybrid immunity group, n=15). Different colours used to depict convalescents with asymptomatic or symptomatic SARS-CoV-2 infection. **(B to E)** Levels of IgG against Spike (B and D) and RBD (C and E) in serum and bronchoalveolar lavage (BAL) fluid of control (n=11), vaccinated (n=7) and infected vaccinated donors (n=15). **(F to G)** Levels of IgA against Spike (F) and RBD (G) in BAL fluid of control (n=11), vaccinated (n=7) and infected, vaccinated donors (n=15). Antibody levels are expressed as arbitrary units. Homologous vaccination with ChAdOX1_S or mRNA vaccine is depicted with an open or close circle, respectively. Data shown are in median and interquartile range (IQR). Statistical differences were determined by Kruskal-Wallis test following correction for multiple comparisons. Adjusted p values are indicated by *(p < 0.05), **(p < 0.01) and ****(p < 0.0001).

Extended Data Figure 1. Associations between lung mucosa and systemic antibody levels against Spike post SARS-CoV-2 vaccination. (A to C) Levels of anti-N IgG in serum (A) and anti-N IgG (B) and IgA (C) in BAL fluid of control (n=11), naïve vaccinated (n=7) and infected vaccinated donors (n=15). Correlation of anti-S IgG **(D)** and anti-S IgA **(E)** levels measured in serum and BAL fluid of naïve, vaccinated (in turquoise) and infected, vaccinated donors (in purple). Total n=22 vaccinated individuals. R and p values are shown using Spearman rank correlation.

Figure 2. Detectable anti-SARS-CoV-2 memory B cell responses in the lung mucosa following infection and vaccination. A) Example flow cytometry plots of Spike-, RBD- and N-specific global memory B cells (MBCs) in PBMC and BAL sample of an unexposed pre-pandemic control (left) and an infected vaccinated donor(right) (see extended data fig.2 for full gating). **B-D)** Frequency of circulating Spike-, RBD- and N-specific MBCs in control (n=10), naïve, vaccinated (n=7) and infected, vaccinated donors (n=15). **E-G)** Frequency of Spike-, RBD- and N-specific MBCs detected in BAL samples of control (n=6) and infected vaccinated donors (n=9). **H)** Frequency of SARS-CoV-2 specific memory B cells in blood (PBMC) and BAL, shown as paired samples, of infected vaccinated donors. **(I)** Distribution of global MBC subsets in PBMC and BAL based on the expression of IgD and IgM in control and infected, vaccinated donors together (n=25). Homologous vaccination with ChAdOX1_S or mRNA

vaccine is depicted with an open or close circle, respectively. Data shown are in median and interquartile range (IQR). Statistical differences were determined by Kruskal-Wallis test following correction for multiple comparisons (**B-D**), Mann-Whitney U test (**E-G**) and Wilcoxon's paired test (**H-I**). P values are indicated by *($p < 0.05$), **($p < 0.01$), ***($p < 0.001$) and ****($p < 0.0001$).

Extended Data Figure 2. Memory B cells and SARS-CoV-2 specific B cells responses in human blood and BAL. **A)** Gating strategy of B cells in human PBMC or BAL sample, with representative flow cytometry plots of SARS-CoV-2 specific B cells from controls and infected, vaccinated donors. **B)** Frequency of circulating SARS-CoV-2 MBCs in mRNA (n=10) or ChAdOxAd1_S vaccine (n=5) recipients with prior infection. **C)** Frequency of lower airway Spike MBCs in mRNA (close circles, n=6) or ChAdOxAd1_S vaccine (open circles, n=3) recipients with prior infection. Data shown are in median and interquartile range (IQR). Statistical differences were determined by Mann-Whitney U test. P values are indicated by *($p < 0.05$), **($p < 0.01$) and ****($p < 0.0001$).

Figure 3. Detection of S-specific T cells responses in the lung mucosa after infection and vaccination but not following vaccination alone. **A)** Representative flow cytometry plots of S-specific CD4⁺ and CD8⁺ T cells in PBMC and BAL sample (on the left) and S-specific TRM CD4⁺ and CD8⁺ T cells in BAL sample (on the right) of an infected, vaccinated donor. Identification of Spike specific T cells was based on the AIM assay, assessing co-expression CD40L and OX40 on CD4⁺ T cells and co-expression of CD25 and 4-1BB on CD8⁺ T cells after stimulation with Spike megapools. **B-C)** Frequency of circulating S-specific CD4⁺ and CD8⁺ T cells in control (n=8), naïve, vaccinated (n= 6) and infected, vaccinated donors (n= 13). **D-G)** Frequency of lower-airway S-specific CD4⁺ and CD8⁺ T cells within the global (D-E) and TRM compartment (F-G) in control (n=8), naïve, vaccinated (n= 6) and infected, vaccinated donors (n= 13). **H-I)** Frequency of S-specific CD4⁺ and CD8⁺ T cells in PBMC and BAL, shown as paired samples, of naïve, vaccinated, and infected vaccinated donors. Homologous vaccination with ChAdOX1_S or mRNA vaccine is depicted with an open or close circle, respectively. Data shown are in median and interquartile range (IQR). Statistical differences were determined by Kruskal-Wallis test following correction for multiple comparisons (**B-G**) and Wilcoxon's paired test (**H-I**). P values are indicated by *($p < 0.05$), **($p < 0.01$), ***($p < 0.001$) and ****($p < 0.0001$).

Extended Data Figure 3. **A)** Example gating of T cell staining after overnight stimulation with SARS-CoV-2 peptide pools. Lymphocytes (SSC-H vs. FSC-H), single cells (FSC-H vs. FSC-

A), Live cells (fixable live/dead), CD3⁺, CD4⁺ or CD8⁺ or MAIT cells. Tissue resident memory (TRM) CD4⁺ and CD8⁺ T cells were defined as CD4⁺CD69⁺CD49a⁺ and CD8⁺CD69⁺CD103⁺, respectively. **B)** Representative plots of SARS-CoV-2 specific CD4⁺ and CD8⁺ T cells in PBMC and BAL of an infected, vaccinated donor after overnight stimulation with SARS-CoV-2 peptide pools. DMSO was used as a negative control. **B-C)** Frequency of circulating and lower-airway S-specific CD4⁺ and CD8⁺ T cells in mRNA (n=9) or ChAdOxAd1_S vaccine (n=5) recipients with prior infection. **D-E)** Paired analysis of proportions of CD4⁺ and CD8⁺ T cells which recognise SARS-CoV-2 antigens in BAL and paired blood. Statistical differences were determined by Mann-Whitney U test. *(p < 0.05).

Figure 4. Detection of infection-induced SARS-CoV-2 T cell responses in the periphery and lung mucosa. A-B) Frequency of circulating N-, M- and RTC-specific CD4⁺ and CD8⁺ T cells in control (n=8), naïve, vaccinated (n= 6) and infected, vaccinated donors (n= 13). **C-F)** Frequency of N-, M- and RTC-specific CD4⁺ and CD8⁺ T cells within the global and TRM compartment of lower airway T cells in control (n=4) and infected, vaccinated donors (n=8). **G-H)** Frequency of SARS-CoV-2-specific CD4⁺ and CD8⁺ T cells in PBMC and BAL, shown as paired samples, of infected, vaccinated donors. Homologous vaccination with ChAdOX1_S or mRNA vaccine is depicted with an open or close circle, respectively. Data shown are in median and interquartile range (IQR). Statistical differences were determined by Kruskal-Wallis test following correction for multiple comparisons (**A-B**), Mann-Whitney U test (**E-F**) and Wilcoxon's paired test (**G-H**). P values are indicated by *(p < 0.05) and **(p < 0.01).

Figure 5. Long-lived IgG but short-term IgA responses to SARS-CoV-2 antigens in the lung mucosa following vaccination and infection. A-B) Correlation between time post-vaccination and levels of IgG to S, RBD and N proteins measured in serum (A) and BAL supernatant (B) of naïve vaccinated (n=7) and infected vaccinated individuals (n=15). **C)** Correlation between time post-vaccination and levels of IgA to S, RBD and N proteins measured in BAL supernatant of naïve, vaccinated (n=7) and infected, vaccinated individuals (n=15). Homologous vaccination with ChAdOX1_S or mRNA vaccine is depicted with an open or close circle, respectively. Spearman correlation used. R and p values are shown.

Figure 6. Persistent S-specific T cells in the lung mucosa following hybrid immunity. A) Correlation between time post-vaccination and the frequency of S-specific CD4⁺ (left) and CD8⁺ T cells (right) detected in the blood of naïve vaccinated (n=6) and infected vaccinated individuals (n=15). **B-C)** Correlation between time post-vaccination and the frequency of S-specific CD4⁺ (left) and CD8⁺ T cells (right) in the global and TRM compartment of lower-

airway T cells in BAL of naïve, vaccinated (n=6) and infected, vaccinated individuals (n=15). Homologous vaccination with ChAdOX1_S or mRNA vaccine is depicted with an open or close circle, respectively. D) Correlation between time post infection from symptoms onset and the frequency of N-, M and RTC- specific CD4⁺ (left) and CD8⁺ T cells (right) detected in BAL of infected, vaccinated individuals with symptomatic, PCR-confirmed SARS-CoV-2 infection (n=13). Spearman correlation used. R and p values are shown.





Figure 1



Extended Data Figure 1

A







Figure 2



Extended Data Figure 2








Figure 3


A




bioRxiv preprint doi: <https://doi.org/10.1101/2023.01.25.525488>; this version posted January 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license.




B




C



D




E




Extended Data Figure 3

Blood

A




B




BAL


C




D




E



F



G



H





Figure 4



BAL






Figure 5

Blood



BAL






Figure 6